Latest news with #RealGUIDE
Yahoo
3 days ago
- Business
- Yahoo
ZimVie Stock Gains Following the Launch of RealGUIDE Software Suite
ZimVie Inc. ZIMV recently launched its RealGUIDE Software Suite and Implant Concierge service in Japan. The RealGUIDE platform enables streamlined workflows and enhanced treatment accuracy, while the Implant Concierge service offers personalized support to clinicians throughout the implant process. Together, these solutions aim to boost clinical efficiency and improve patient outcomes in Japan's rapidly evolving dental landscape. As ZimVie's largest market in the Asia-Pacific region, Japan represents a key growth opportunity. The launch is expected to enhance clinician access to end-to-end, vertically integrated digital workflows, reinforcing ZimVie's strategic focus on innovation and global market penetration. Following the announcement, shares of the company have gained 2.9% and closed at $9.38 on Friday. However, in the year-to-date period, ZIMV's shares have lost 32.7% against the industry's 5.9% growth. The S&P 500 increased 1.5% in the same time frame. The launch of the RealGUIDE Software Suite and Implant Concierge service in Japan positions ZimVie to capture a larger share of a high-potential market by offering advanced digital solutions that align with the global shift toward precision-driven, technology-enabled dentistry. By streamlining workflows and enhancing clinician efficiency, these tools can drive increased adoption of ZimVie implants and related products, fostering customer loyalty and recurring revenue. Over time, this strategic move could strengthen ZimVie's footprint in the APAC region, support margin expansion through high-value services, and contribute to sustainable long-term growth. Meanwhile, ZIMV currently has a market capitalization of $261.2 million. Image Source: Zacks Investment Research ZimVie's launch of the RealGUIDE Software Suite in Japan marks a major advancement in digital implantology, offering dentists a robust, cloud-based platform for precise implant planning, surgical guide design and restorative workflows. As the first fully cloud-integrated system of its kind, RealGUIDE allows clinicians to customize their digital workflows using modular components tailored to diagnostic, surgical, and restorative needs. The integration with ZimVie's Dental Technology Institute and its CAD/CAM milling capabilities ensures a seamless transition from case planning to final restoration, significantly improving treatment accuracy, reducing turnaround times, and enhancing patient care. This end-to-end digital experience is poised to streamline operations for clinics while improving efficiency, precision and cost-effectiveness. Complementing the RealGUIDE platform is the Implant Concierge service, a scalable virtual outsourcing solution that supports clinicians in planning and executing guided surgeries with minimal complexity. Designed for user-friendliness and zero upfront investment, Implant Concierge brings together a team of expert treatment planners and designers to ensure accuracy at every step. It integrates directly with dental labs to offer a smooth, fully coordinated experience from planning to final placement, especially beneficial for high-volume practices. Per a report by MarketsandMarkets, the global digital dentistry market, valued at $6.5 billion in 2022, is forecasted to grow at a robust CAGR of 10.9%, reaching $12.2 billion by 2028. The digital dentistry market is rising due to the growing demand for faster, more accurate, and patient-friendly dental procedures. Advancements in 3D imaging, CAD/CAM systems, and cloud-based software are enabling dentists to deliver personalized treatments with greater precision and efficiency. ZIMV carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report ZimVie Inc. (ZIMV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
05-06-2025
- Business
- Associated Press
ZimVie Announces Launch of RealGUIDE® Dental Implant Software Suite and Implant Concierge® Service in Japan
PALM BEACH GARDENS, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its RealGUIDE® Software Suite and Implant Concierge® service in Japan. The launch of RealGUIDE and Implant Concierge in Japan expands dentists' access to a unique digital dental implant ecosystem—from implant planning to placement—with vertically integrated, end-to-end solutions. The dental implant market opportunity in Japan is significant, and Japan is ZimVie's largest market in the APAC region. 'We are proud to offer an innovative digital dentistry solution tailored to the needs of the Japanese market,' said Taishi Kondo, General Manager, Japan. 'These launches are a significant step forward in supporting our customers in delivering new practice efficiencies and high-quality implant care with confidence.' RealGUIDE software provides dentists with everything needed for precise implant planning, surgical guides, and restorative design to elevate patient care while delivering workflow, time, and cost efficiencies. The first complete cloud-based solution of its kind, RealGUIDE consists of several software modules that may be combined as desired for a thorough diagnosis, intended implant positioning, advanced surgical guide design, and cutting-edge restorative design and manufacturing. RealGUIDE software will be integrated with ZimVie's fully owned dental laboratory Dental Technology Institute (DTI) in Japan and its CAD/CAM milling workflow to provide clinicians with a seamless digital dentistry experience—from case planning to final restoration. Implant Concierge is a virtual outsourcing service that simplifies and streamlines implant treatment planning and guided surgery. A user-friendly platform with no upfront investment, it consolidates essential services to reduce complexity and accelerate case turnaround. The solution is fully scalable to support high-volume practices and seamlessly integrates with dental laboratories, ensuring a smooth workflow from start to finish. Together, an expert team of treatment planners, designers, and guided surgery support ensure accuracy and predictability for all experience levels. 'The rising adoption of dental implants presents a significant growth opportunity, and with it, a clear need for more efficient, accurate, and integrated treatment workflows,' said ZimVie CEO Vafa Jamali. 'Digital dentistry is at the forefront of this shift, quickly establishing itself as the new standard in implantology. We have seen tremendous traction in other markets with RealGUIDE and Implant Concierge and are excited to expand into yet another growing and increasingly sophisticated market.' For more information on ZimVie's RealGUIDE, Implant Concierge, dental implants, suite of connected solutions, and continuing education, please visit For more information about ZimVie Japan and DTI, please visit and About ZimVie ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie's filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release. Media Contact Information: ZimVie Grace Flowers • [email protected] (561) 319-6130 Investor Contact Information: Gilmartin Group LLC Webb Campbell • [email protected]
